Pfizer profit doubles on drug sales, lower costs
NEW YORK (Reuters) - Pfizer Inc on Wednesday said second-quarter earnings more than doubled on higher sales of its prescription drugs, lower expenses and overseas sales that were boosted by the weak dollar.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=Wu6rrS" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=Wu6rrS)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=yeZbtJ" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=yeZbtJ) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=zOdOyj" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=zOdOyj) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=61lenj" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=61lenj)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/343465960" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/343465960/idUSWNAB190020080723